Want to see IN:ERIS full AI Analyst Report?
ERIS Stock Chart & Stats
₹1398.90
₹2.90(0.21%)
At close: 4:00 PM EDT
₹1398.90
₹2.90(0.21%)
Day’s Range― - ―
52-Week Range₹1,114.25 - ₹1,737.00
Previous CloseN/A
Volume38.23K
Average Volume (3M)19.27K
Market Cap
₹156.18B
Enterprise Value₹200.57B
Total Cash (Recent Filing)₹673.00M
Total Debt (Recent Filing)₹23.59B
Price to Earnings (P/E)24.3
Beta0.78
Next Earnings
Oct 26, 2026EPS Estimate
10.62Next Dividend Ex-DateN/A
Dividend Yield0.64%
Share Statistics
EPS (TTM)45.40
Shares Outstanding138,738,570
10 Day Avg. Volume44,375
30 Day Avg. Volume19,266
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)4.54
Price to Sales (P/S)5.67
P/FCF Ratio354.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)45.65
Revenue Forecast (FY)₹35.32B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityStrong FY2026 gross, EBIT, and net margins show the branded portfolio is producing substantial operating and bottom-line profit. This profitability provides capacity to support product launches, sales activity, and balance-sheet needs, while sharply higher net income reinforces durable earnings strength.
Chronic Branded PortfolioA prescription-led branded portfolio focused on chronic and lifestyle therapies can support repeat demand because treatment often continues over time. This model, supported by doctor engagement and an established domestic sales force, offers a durable foundation for brand retention and recurring revenue.
Improving LeverageLower debt-to-equity versus FY2024 indicates improved balance-sheet discipline and reduces financial pressure relative to the company’s recent peak leverage. Solid return on equity also suggests that capital is being used productively, supporting greater flexibility for ongoing operations and investment.
Bears Say
Weak Cash ConversionThe sharp decline in free cash flow and very low coverage of net income indicate that reported profits are not translating reliably into cash. Persistent weak conversion could constrain internally funded growth, reduce capital-allocation flexibility, and make earnings quality more dependent on working-capital movements.
Higher Historical LeverageAlthough leverage has improved recently, debt remains meaningfully higher than the company’s earlier near-zero baseline. This raises structural financial risk compared with its historical position, as interest and repayment obligations can limit flexibility if operating performance or cash generation weakens.
Margin VolatilityThe normalization of gross margin after an unusually strong FY2025 level shows that profitability is not fully stable across periods. Margin swings can make earnings less predictable, complicate forecasting, and reduce confidence that current profit levels will persist without favorable product mix or operating conditions.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1114.25 and its highest was ₹1737.00 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹156.18B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is Oct 26, 2026 which is in 5 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Jul 29, 2026. The company reported ₹10.3 earnings per share for the quarter, missing the consensus estimate of ₹10.767 by -₹0.467.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Notavailable dividend of ₹7.21 which represents an annual dividend yield of 0.64%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 10.62.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,738,570 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹10.3 in its last earnings report, missing expectations of ₹10.767. Following the earnings report the stock price went up 2.573%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Alembic Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Torrent Pharmaceuticals Ltd
―